309P Antineoplastic (ANP) therapies (Tx) after alpelisib (ALP) or placebo (PBO) + fulvestrant (FUL) in patients (Pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (Mut) advanced breast cancer (ABC): An analysis from SOLAR-1

Autor:	André, F., Rugo, H.S., Juric, D., Rubovsky, G., Yamashita, T., Stemmer, S.M., Lu, Y-S., Miller, M.K., Lorenzo, I., Hu, H., Ciruelos, E.M.
Zdroj:	In Annals of Oncology September 2021 32 Supplement 5:S498-S499
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu